Compare Nasdaq Inc (NDAQ) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq Inc vs Twist Bioscience Corp — how do they compare? Nasdaq Inc trades at $93.31 (market cap $51.63B), while Twist Bioscience Corp trades at $162.24 (market cap $10.08B). The key difference: Nasdaq Inc is far larger — about 5.1× Twist Bioscience Corp's market cap, and Nasdaq Inc pays a 1.26% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nasdaq Inc for 126 Days and Twist Bioscience Corp for 27 Days on average.
| NDAQ | TWST | |
|---|---|---|
Market Cap | $51.63B | $10.08B |
Volume | 2,668,175 | 4,229,037 |
Sector | Financials | Health |
52-Week High | $100.98 | $205.00 |
52-Week Low | $76.85 | $25.45 |
Typical Hold Time | 126 Days | 27 Days |
Enterprise Value | $58.09B | $10.01B |
Dividend Yield | 1.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nasdaq (NDAQ) trades at $93.51, up 1.72% today, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $8.26B in 2025, with net income margin expanding to 22.52%. Analyst consensus is a Buy with a $110.43 price target, supported by positive news on AI platform adoption and index changes.
Outlook remains positive given earnings momentum and Financial Technology growth, though risks include market volatility and debt levels. The stock offers upside to consensus targets but faces execution risks in tech integration and competitive pressures.
Twist Bioscience (TWST) trades at $162.43, up 4.36% today, showing strong momentum despite recent earnings misses. The stock maintains a bullish technical signal with RSI at 29.02 indicating potential oversold conditions. Fundamentally, revenue growth continues (2025: $377M, 2026: $432M projected) but profitability remains elusive with negative margins. Recent partnership with Eli Lilly's TuneLab platform highlights strategic positioning in AI-driven drug discovery.
While analyst consensus favors Buy (73%), the stock trades above the $145.20 target, suggesting limited near-term upside. Key risks include persistent cash burn (-$44M net CF in 2025) and high valuation multiples (P/S: 21.5). The AI biotech partnership provides growth catalyst potential, but profitability timeline remains uncertain for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
